← Markets

Oculis Holding AG

OCS · NASDAQ

Market closed$12.19$-0.420000 (-3.33%)After hours $12.01 · -1.48%

Key statistics

Previous close$12.61
Open$12.43
Day high$12.76
Day low$12.13
52-week high$34.48
52-week low$10.52
Market cap696.90M
Volume304.13K
Average volume735.89K
P/E ratio-5.72
Forward P/E—
EPS-2.13
Dividend yield0.00%

Market context

Why it moved

OCS shares declined as investor sentiment weakened following concerns about the company's attempt to replicate its National OCS Program internationally, with the market reacting negatively to uncertainty surrounding the expansion strategy.

Investing.comCoSubstackKeenenhFacebook

What is happening

Recent company-specific developments and publisher coverage.

July 18, 2026Oculis Holding AG shares declined in regular trading and continued falling in after-hours, weighed by broader healthcare sector weakness and an ongoing securities law investigation by Johnson Fistel, PLLP into whether the company or its executives violated federal securities laws. The legal overhang adds pressure on the clinical-stage ophthalmic biotech, even as UBS has broadly upgraded healthcare as a key sector allocation, citing improving fundamentals and a warming M&A environment for biotechs.

-3.3307

July 11, 2026Oculis Holding AG closed modestly lower amid a backdrop of mixed catalysts, as investors continue to digest the late-May Phase 3 Diamond trial failure of OCS-01 eye drops for diabetic macular edema—a setback that has weighed heavily on the stock, down over 32% year-to-date. Positive developments remain in focus, however, including the June first patient randomization in the PREDICT-1 trial of licaminlimab, an FDA Special Protocol Assessment agreement for its optic neuritis registrational trial, and a Guggenheim Buy initiation with a $75 price target, suggesting analysts see significant upside from current levels. In after-hours trading, shares are edging higher by roughly 2%, while broader biotech sentiment remains constructive following CNBC commentary highlighting biotech as a market standout.

-0.5109

July 9, 2026Oculis Holding AG shares closed flat in the regular session but slipped in after-hours trading, weighed by lingering investor concern following the late-May Phase 3 failure of OCS-01 in diabetic macular edema—its Diamond trials missed the primary endpoint—which has left the stock down roughly 32% year-to-date. Despite a unanimous Buy consensus from 11 analysts and an average price target of ~$30, the stock remains under pressure as investors await progress on its PREDICT-1 registrational trial for licaminlimab and a planned optic neuritis study, while broader biotech sentiment remains constructive with Cramer calling the sector the market's hottest group amid a favorable M&A backdrop.
July 9, 2026Oculis Holding AG closed modestly higher, edging up about 1% in a session marked by broader market turbulence after President Trump declared the Iran ceasefire deal 'over,' sending oil surging 5%+ and triggering a global risk-off selloff. Healthcare outperformed as investors rotated into defensive and biotech names — XLV notched strong relative strength, with Jim Cramer recently calling biotech 'the hottest group in the market' and predicting an M&A flood under a more favorable FDA. Separately, Oculis disclosed RSU vesting and settlement transactions by a director, a routine insider event with no material impact on outlook.

1.0324

July 7, 2026Oculis Holding AG shares declined after giving back some of Thursday's gains, which had been driven by an FDA Special Protocol Assessment (SPA) agreement for its PIONEER-1 registrational trial evaluating Privosegtor in optic neuritis. The SPA confirms the trial design is adequate to support a future New Drug Application, a meaningful regulatory milestone, though broader healthcare sector weakness — with major names like Pfizer also falling — weighed on sentiment. In after-hours trading, shares recovered modestly.

-2.2663

July 2, 2026Oculis Holding AG jumped ~4.4% as the company announced it will present at the Piper Sandler Virtual Ophthalmology Conference on July 10, spotlighting its two late-stage candidates: Privosegtor (FDA Breakthrough Therapy-designated neuroprotective for optic neuritis, targeting a $7B+ U.S. market) and Licaminlimab (a genotype-based precision medicine for dry eye disease). The move also coincides with Privosegtor advancing into Phase 3 trials and strong institutional interest, including Millennium Management significantly adding to its position in Q1 2026.

4.3607

July 1, 2026Oculis Holding AG closed down 2.45% as the company announced an update advancing privosegtor into a Phase 3 optic neuritis trial, a key clinical milestone investors are monitoring closely. While the biotech sector broadly showed resilience — with the Virtus Biotech Clinical Trials ETF hitting a 52-week high — Oculis shares pulled back on below-average volume, suggesting mixed near-term sentiment despite the pipeline progress and broadly supportive analyst bias.

-2.4513

June 27, 2026Oculis Holding AG closed up 2.21% as the company pivoted its investor narrative following the May 29 failure of its DIAMOND-1 and DIAMOND-2 Phase 3 trials for OCS-01 in diabetic macular edema—a collapse that sent shares down 23%. The fresh corporate presentation highlights a debt-free balance sheet with cash runway into 2H 2029, and two registrational-stage pipeline assets: Privosegtor (FDA Breakthrough Therapy designation, EMA PRIME) for optic neuritis, and Licaminlimab for dry eye disease, with PREDICT-1 topline data expected around year-end 2026. However, the recovery faces a headwind from a Pomerantz Law Firm securities fraud investigation announced June 25.

2.2147

Quiver Quantitative · July 2, 2026Oculis to Present Late-Stage Pipeline Update at Piper Sandler Virtual Ophthalmology ConferenceStock Titan · July 2, 2026Oculis spotlights late-stage eye drugs at Piper Sandler eventStock Titan · June 8, 2026Eye drug maker Oculis to outline $7B+ optic neuritis market planEuropean Biotechnology Magazine · June 1, 2026Oculis drops plans for diabetic macular edema drug after Phase III miss
Benzinga · June 9, 2026Oculis Announces First Patient Randomized In PREDICT-1 Registrational Trial Of Licaminlimab For Dry Eye Disease
Benzinga · June 3, 2026JP Morgan Maintains Overweight on Oculis Holding, Lowers Price Target to $23
Benzinga · June 2, 2026Baird Maintains Outperform on Oculis Holding, Lowers Price Target to $38
Benzinga · June 1, 2026Stifel Maintains Buy on Oculis Holding, Lowers Price Target to $40
Benzinga · June 1, 2026Why Is Oculis Stock Sinking Monday?
Benzinga · June 1, 2026Guggenheim Maintains Buy on Oculis Holding, Lowers Price Target to $45
Benzinga · June 1, 2026Needham Maintains Buy on Oculis Holding, Lowers Price Target to $38
Mt Newswire · June 1, 2026Oculis Says Diabetic Macular Edema Eye Therapy Studies Miss Primary Endpoint

Peers

S&P 500SPX · $7,457.69-1.01%Enliven Therapeutics, Inc.ELVN · $53.20+4.60%Disc Medicine, Inc.IRON · $76.15+3.65%Vera Therapeutics, Inc.VERA · $38.50-1.58%Tarsus Pharmaceuticals, Inc.TARS · $59.85+3.74%uniQure N.V.QURE · $40.25+2.26%ProQR Therapeutics N.V.PRQR · $1.70+1.80%AlvotechALVO · $3.46+2.67%MapLight Therapeutics, Inc.MPLT · $37.87+1.75%REGENXBIO Inc.RGNX · $9.89-11.70%Aldeyra TheALDX · $1.69-1.74%